Ingliforib

Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC₅₀s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity. IC50 & Target: IC50: 52 nM (liver Glycogen phosphorylase), 352 nM (Muscle Glycogen phosphorylase), 150 nM (Barin Glycogen phosphorylase)^[1] In Vitro: Ingliforib is a glycogen phosphorylase inhibitor, and inhibits the myocardial GP isoforms (muscle and brain) with IC₅₀s of 352 and 150 nM, respectively, also a potent inhibitor of the liver isoform (IC₅₀ of 52 nM). Ingliforib (0.1, 1, 10 μM) dose-dependently reduces infarct size in the isolated rabbit hearts^[1]. In Vivo: Ingliforib (15 mg/kg) potently reduces infarct size by 52%, and decreases plasma glucose and lactate concentrations in openchest anesthetized rabbits. Ingliforib (15 mg/kg) also inhibits myocardial glycogen phosphorylase a (GPa) and total glycogen phosphorylase (GP) activity in anesthetized rabbits^[1].